Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Arena Pharmaceuticals (ARNA)

Arena Pharmaceuticals (ARNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arena Pharmaceuticals 136 Heber Avenue Suite 204 Park City UT 84060 USA

P: 858-453-7200

Description:

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their first and only drug approved by any regulatory agency for marketing. BELVIQ was approved by the US Food and Drug Administration, or FDA, for marketing in the United States, and was made available by prescription in June 2013 to adults who are overweight with a comorbidity or obese. They are exploring BELVIQ for possible new indications, using different formulations, and in combination with other drugs.

Key Statistics

Overview:

Market Capitalization, $K 6,165,283
Shares Outstanding, K 61,659
Annual Sales, $ 50 K
Annual Net Income, $ -616,430 K
Last Quarter Sales, $ 50 K
Last Quarter Net Income, $ -155,610 K
60-Month Beta 0.55
% of Insider Shareholders 3.05%
% of Institutional Shareholders 83.77%
Float, K 59,778
% Float 96.95%

Growth:

1-Year Return 35.51%
3-Year Return 115.36%
5-Year Return 545.10%
5-Year Revenue Growth -99.96%
5-Year Earnings Growth -1,026.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.54 on 02/23/22
Next Earnings Date 05/04/22
Earnings Per Share ttm -10.13
EPS Growth vs. Prev Qtr 20.87%
EPS Growth vs. Prev Year -20.95%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 06/19/17

ARNA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -69.83%
Return-on-Assets % -62.36%
Profit Margin % -1,232,859.97
Net Margin % -676.30
Debt/Equity 0.05
Price/Sales 114,103.41
Price/Cash Flow N/A
Price/Book 9.14
Book Value/Share 10.94
Interest Coverage -147.18
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar